Poster 223: Patient Reported Outcomes Following Treatment with Leukocyte Rich Platelet Rich Plasma Injections for Proximal Hamstring Tendinopathy

Objectives: The potential applications of platelet rich plasma (PRP) in orthopedics are vast, yet there remain many unanswered questions regarding the use PRP for treatment soft tissue pathologies. For tendon injuries, is strong evidence recommending leukocyte-rich (LR-PRP) lateral epicondylitis and promising patellar tendinopathy rotator cuff injuries (1-4). Apart from these conditions, supporting routine tendinopathies mixed or lacking standardization. Proximal hamstring (PHT) a common condition that can cause significant pain dysfunction active patients, recreational athletes, professional athletes alike (5,6). Hamstring account 12-29% all approximately 12% proximal (7-13). Currently, body research detailing PHT sparse. A prospective cohort study one retrospective chart review evaluated leukocyte poor PRP; found no difference patient reported outcomes (PROs) while 80% subjective improvement (6,15). Three more Level IV studies patient-reported function scores following but did not consistently report type used (16-18). None included information on volume injected amount time blood draw to injection. has generated much interest orthopedic sports community given prospects enhanced healing, improved function, reduced pain. However, current literature assessing efficacy mixed. sound scientific principles behind PRP, success other tendinopathies, high prevalence urge us better understand role treatment. This examines effect standardized LR-PRP injections physical at 2-week, 3 months, 6-month timepoints. also evaluates any impact drawn administration may have PROs. Methods: Following IRB approval, subjects who were enrolled Data Registry had injection documented this study. Exclusion criterion was age less than 18 years. All prepared same fashion administeredby physician using Zimmer Biomet with GPS III Platelet Concentration System. Each 25-25.5 cc per hamstring, 4.5-5cc anticoagulant added. centrifuged 15 minutes resulting 2- 6ml LR-PRP. collection centrifuge, LP-PRP under ultrasound guidance. De-identified data collected September 2020 August 2022. When bilateral occurred, each treated separately. items collected: injection, injected, PRO measures, unique survey (Table 1). one-sided paired t-test completed patient’s score between baseline intervals (alpha 0.05) summary statistics collected. Pearson correlations performed results as well results. Results: 16 patients (17 hips) met inclusion criteria. 6 forms various timepoints 2). surveys demonstrated Table 1. median 3.2mL (2.5mL – 4mL) 34.0 (18 50 minutes). An increasing proportion satisfaction their across PROMIS Pain significantly vs 2WPI (p = 0.03551, n 17), 3MPI 0.003371, 15), 6MPI 0.006832, 11) 1YPI 0.01858, 6). Physical Function test showed 0.03042, 14), 0.01469, 0.04541, iHOT 1 year post 0.03936, 5). There correlation (r -9023969). moderate both 0.6775792) -0.6559364). Conclusions: aimed examine assess related demonstrate Functions months compared baseline. increased scores. Correlations measures. While currently limited by small sample size, here part growing database injections. add support improving hip associated PHT. [Table: see text][Table: text]